Policies
Please note, the policies on this page are currently being reviewed and will be updated as soon as possible.
Specialised Commissioning Group Treatment Policies
Policy on the use of cranial banding in the treatment of positional plagiocephaly and brachycephaly
Age related macular degeneration
Ranibizumab - guide to commencing, continuing & discontinuing treatment
Deep brain stimulation for movement disorders
Bone marrow transplant - adults & children
Specialised adult morbid obesity surgery (interim policy)
Gender dysphoria
Regional PFO guidance
Cochlear implants
Immunoglobulins for intravenous & subcutaneous use
Fertility policy
Penile Prostheses for erectile dysfunction
Sarcral Nerve Stimulation
Spinal Cord Stimulation for intractable chronic pain
Specialised Commissioning Group Cancer Drug Policies
Bortezomib for multiple myeloma
Thalidomide for multiple myeloma
Lenalidomide for multiple myeloma
Cetuximab for head and neck cancer
Cetuximab for first line colorectal cancer
Bevacizumab, sorafenib, temsirolimus & sunitnib for renal cancer
Rituximab for chronic lymphocytic leukaemia
Sunitinib for malignant gastrointestinal stromal tumour
Pemetrexed for non small cell lung cancer
Cetuximab for third line k-ras wild type metastatic colorectal cancer
Topotecan for cervical cancer
Topotecan for lung cancer
Bevacizumab for MBC (metastatic breast cancer)
Abraxane for breast cancer
Docetaxel for head and neck cancer
Everolimus for metastatic renal cell carcinoma
Trabectedin for sarcoma
Gefitnib for locally advanced or metastatic non-small-cell lung cancer (NSCLC)
Sorafenib for helpatocellular carcinoma
Pemetrexed maintenance for non-small-cell lung cancer
Gefitinib for locally advanced or metastatic NSCLC
Capecitabine for gastric cancer
Rituximab for relapsed or refactory CLL
Imatinib for GIST
Bevacizumab for metastatic colorectal cancer
Cetuximab for 2nd line and subsequent metostatic colorectal cancer
Gemcitabine IV infusion Capecitabine 150mg or 500mg tablets for metastatic adenocarcinoma of the pancreas
Imatinib for gaastrointestinal stromal tumours
Ofatumumab for chronic lymphocytic leukaemia
Trastuzumba for gastric cancer (HR2-positive metastatic)
Alemtuzumab for B-cell chronic lymphocytic leukeamia
Azacitidine for myelodysplasia
Bortezomib (with melphalan & prednisolone)
Clofarabine for acute lymphoblastic leukeamia
Dasatinib for acute lymphoblastic leukeamia & chronic myeloid leukaemia
Erlotinib for non-small cell lung cancer
Imatinib for acute lymphoblastic leukeamia
Lapatinib (with Capecitabine) for breast cancer
Pemetrexed for non-small cell lung cancer (2nd line)
Rituximab for follicular lymphoma (1st line maintenance)
Sunitinib for advanced pancreatic neuroendocrine tumours (NET)
Topotecan (with cisplatin) for cervical cancer
Bevacizumab for metastatic breast cancer
Bendamustine for chronic lymphocytic leukeamia
Pazopanib for renal cell carcinoma
Trabectedin for Relapsed Ovarian Cancer
Rituximab for maintenance of follicular non-hodgkins lymphoma
Erlotinib for non-small cell lung cancer (maintenance)
Lenalidomide for transfusion dependent anaemia due to MDS
Rituximab for EBV reaction
Eribulin for locally advanced metastatic breast cancer
Specialised Commissioning Group Non Cancer Drug Policies
Criteria for the use of disease modifying therapies for patients with MS
Pulmonary hypertension
Palivizumab for RSV prophylaxis
Rtiuximab for severe rheumatoid arthritis
Extavia for MS
Sativex for MS
Antifunals for chronic pulmonary aspergillosis
Somathropin for growth failure in children
Armour Thyroid for hypothyroidism
Botulinum toxin type A for excessive sweating
Botulinum toxin A, Vistabel, Dysport, Xeomin, Azzalure for overactive bladder
Bottulinum toxin type A, Vistable, Dysport, Xeomin, Azzalure for prophylaxis of migraine
Botulinum toxin A, Vistabel, Dysport, Xeomin, Azzalure for anal fissures
Co-careldopa 2000mg/500mg intestinal gel for administration via PEG tube for advanced levodopa-responsive Parkinson's disease
Infliximab for hidradenitis suppurtiva
Mecasermin for growth failure in children and adolescents
Rituximab for SLE in adults
Fingolimod for MS
Romiplostin for Thrombocylopenic Purpura
Siklos for Sickle Syndrome
Rituximab for vasculititis (incl. Wegners Granulomatosis)
Plerixafor for Stem Cell Mobilisation
Specialised Commissioning Group Drug Policies (Primary Care Interface Policies)
Fesoterodine for overactive bladder
Testosterone Patch for HSDD
Ivabradine for chronic stable angina pectoris
Liraglutide for adults with type 2 diabetes mellitus
Nebivolol for stable milkd moderate chronic heart failure
NuvaRing for contraception
Prostagladin Analogues for glaucoma & ocular hypertension
Proton Pump Inhibitors for (see individual SmPCs)
Ranolazine modified release for stable angina pectoris
Retapamulin 1% for superficial skin infections
Sitagliptin for glycaemic control in type 2 diabetes
Solifenacin for overactive bladder
Buprenorphone/Naloxone for opiod drug dependence
Oxycodone/Nalaxone prolonged release for severe pain
Ulpristal Acetat for emergency contraception
Vildagliptin for type 2 diabetes (dual therapy in combination)
NHS Kirklees Individual Funding Request Commissioning Policies
Policy & procedures for managing individual funding requests
Prior approvals policy - dilation & curettage/hysterosopy
Prior approvals policy - grommets
Prior approvals policy - hysterectomy (for heavy menstrual bleeding)
Prior approvals policy - tonsillectomy
Individual Funding Requests process - Information for patients
NHS Kirklees Medicines Commissioning Policies
Ustekinumab Psoriasis
Adalimumab Ankylosing Sponylitits
Adalimumab Crohns
Adalimumab Psoriasis
Etanercept Ankylosing Spondylitis
Etanercept Psoriasis
Infliximab Anklosing Spondylitis
Infliximab Crohns
Infliximab Psoriasis
Infliximab Ulcerative Colitis
Toxilzumab Rheumatoid Arthritis
Pegfilgrastim in Neutropenia
Filgrastim in Netropenia
Travel medicines & vaccination policy
